{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T19:04:17Z","timestamp":1773342257466,"version":"3.50.1"},"reference-count":22,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T00:00:00Z","timestamp":1329436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:p><jats:bold>BACKGROUND:<\/jats:bold> The overall risk of hemolytic transfusion reactions (HTRs) from plasma (minor)\u2010incompatible platelet (PLT) transfusions and the role of a critical anti\u2010A or anti\u2010B titer in predicting and preventing these reactions has not been clearly established.<\/jats:p><jats:p><jats:bold>STUDY DESIGN AND METHODS:<\/jats:bold> We evaluated all apheresis PLT (AP) transfusions for 3 months. Using the gel titer method, we determined the anti\u2010A and\/or the anti\u2010B immunoglobulin (Ig)G titer for all incompatible APs. Reported febrile transfusion reactions and HTRs were recorded; transfusions were not prospectively evaluated by the study team. A posttransfusion direct antiglobulin test (DAT) and eluate were performed after a reported febrile or hemolytic reaction for patients who received plasma\u2010incompatible APs.<\/jats:p><jats:p><jats:bold>RESULTS:<\/jats:bold> A total of 647 of 4288 AP transfusions (15.1%) were plasma incompatible. Group O APs (n\u2003=\u2003278) had significantly higher anti\u2010A and anti\u2010B titers than group A or B APs (p\u2003&lt;\u20030.0001). No group A or B APs had a titer of more than 128 (0\/342). For group O APs, 73 had titers of 256 or greater (26.3%), and 27 had titers of 512 or greater (9.7%). No HTRs were reported to any plasma\u2010incompatible AP transfusion during the study period. Two plasma\u2010incompatible AP transfusions were associated with fever and chills and positive DATs, of which one had a positive eluate. The incidence of a DAT and eluate\u2010positive febrile transfusion reaction in the plasma\u2010incompatible AP population is 0.15% (95% confidence interval, 0.0%\u20100.86%).<\/jats:p><jats:p><jats:bold>CONCLUSION:<\/jats:bold> A critical anti\u2010A or \u2010B titer is not sufficient to predict the risk of hemolysis in patients receiving plasma\u2010incompatible APs, although underreporting of reactions to the blood bank may limit the generalizability of this study.<\/jats:p>","DOI":"10.1111\/j.1537-2995.2012.03574.x","type":"journal-article","created":{"date-parts":[[2012,2,17]],"date-time":"2012-02-17T07:45:31Z","timestamp":1329464731000},"page":"2087-2093","source":"Crossref","is-referenced-by-count":82,"title":["ABO antibody titers are not predictive of hemolytic reactions due to plasma\u2010incompatible platelet transfusions"],"prefix":"10.1111","volume":"52","author":[{"given":"Matthew S.","family":"Karafin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine","family":"Blagg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron A.R.","family":"Tobian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen E.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Ness","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,17]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2009.10.013"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1975.15175103502.x"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1982.tb00514.x"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2010.02759.x"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1998.38198141498.x"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40080902.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01814.x"},{"key":"e_1_2_8_9_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21307\/immunohematology-2019-314","article-title":"ABO and platelet transfusion therapy","volume":"23","author":"Cooling L","year":"2007","journal-title":"Immunohematology"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.5858\/2007-131-909-TOPCAP"},{"key":"e_1_2_8_11_2","volume-title":"Standards for blood banks and transfusion services","author":"American Association of Blood Banks","year":"2009"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2004.03290.x"},{"key":"e_1_2_8_13_2","first-page":"36A","article-title":"The risk of hemolytic transfusion reactions due to passively\u2010acquired ABO antibodies: a retrospective study of non\u2010group O adult recipients of group O plateletpheresis transfusions [abstract]","volume":"44","author":"Fauzie D","year":"2004","journal-title":"Transfusion"},{"key":"e_1_2_8_14_2","unstructured":"EllsworthB EllsworthP StevensWT.NHSN Biovigilance Component Protocol v1.3.1.2011. [cited 2012 Feb 3]. Available from: URL:http:\/\/www.aabb.org\/programs\/biovigilance\/Documents\/diagnose_full.html"},{"key":"e_1_2_8_15_2","volume-title":"Technical manual","author":"Roback JD","year":"2008"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.1984.24585017836.x"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/jca.20072"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3148.2006.00684.x"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tmrv.2006.05.002"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2008.07022.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1537-2995.2000.40040398.x"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2008.01918.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-020131"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1537-2995.2012.03574.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1537-2995.2012.03574.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,14]],"date-time":"2023-10-14T01:21:34Z","timestamp":1697246494000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1537-2995.2012.03574.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,17]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1537-2995.2012.03574.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1537-2995.2012.03574.x","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,17]]}}}